Stoke Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$25.00

−8.93%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $27.45
Volume: 1
Day's high: —
Day's low: —

In brief

Stoke Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.61B.
Its shares closed at $27.45 on 4 Nov 2026, up 8.3% over the past year.
From India you can buy STOK in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Stoke Therapeutics, Inc. (STOK) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole STOK share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade STOK options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +12.6% (SPY −1.6%, XLV +13.5%). 3 months: −14.0% (SPY −0.4%, XLV +15.5%). 1 year: +8.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: STOK, SPY and XLV · as of 4 Nov 2026
12.3 days to cover short interest
10.3M shares were sold short at the 15 Oct 2026 settlement, 15.9% of the 64.5M shares outstanding; covering them would take 12.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $27.45 was 1.3% above its 50-day average ($27.09) and 11.1% below its 200-day average ($30.89). It has closed below the 200-day for 48 sessions, since 28 Aug 2026. The 50-day average crossed below the 200-day on 7 Jul 2026, 85 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
32% of the way up its 52-week range
Closed at $27.45 on 4 Nov 2026: 31.8% below the 52-week high of $40.22 (10 Mar 2026) and 28.5% above the low of $21.37 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+12.6%

6 months−17.5%

1 year+8.3%

5 years+5.5%

Newswire

About

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Website

Notable moves

March 27, 2024
+37.71%
March 26, 2024
+58.31%
July 25, 2023
−32.11%

Newswire

About

Website

Notable moves

March 27, 2024
+37.71%
March 26, 2024
+58.31%
July 25, 2023
−32.11%

Stoke Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$25.00

−8.93%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $27.45
Volume: 1
Day's high: —
Day's low: —

In brief

Stoke Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $1.61B.
Its shares closed at $27.45 on 4 Nov 2026, up 8.3% over the past year.
From India you can buy STOK in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Stoke Therapeutics, Inc. (STOK) shares from India?

Do I need the price of a whole STOK share to invest?

How much can I invest in US stocks in a year?

Can I trade STOK options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +12.6% (SPY −1.6%, XLV +13.5%). 3 months: −14.0% (SPY −0.4%, XLV +15.5%). 1 year: +8.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: STOK, SPY and XLV · as of 4 Nov 2026
12.3 days to cover short interest
10.3M shares were sold short at the 15 Oct 2026 settlement, 15.9% of the 64.5M shares outstanding; covering them would take 12.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $27.45 was 1.3% above its 50-day average ($27.09) and 11.1% below its 200-day average ($30.89). It has closed below the 200-day for 48 sessions, since 28 Aug 2026. The 50-day average crossed below the 200-day on 7 Jul 2026, 85 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
32% of the way up its 52-week range
Closed at $27.45 on 4 Nov 2026: 31.8% below the 52-week high of $40.22 (10 Mar 2026) and 28.5% above the low of $21.37 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+12.6%

6 months−17.5%

1 year+8.3%

5 years+5.5%

Newswire

About

Website

Notable moves

March 27, 2024
+37.71%
March 26, 2024
+58.31%
July 25, 2023
−32.11%

Newswire

About

Website

Notable moves

March 27, 2024
+37.71%
March 26, 2024
+58.31%
July 25, 2023
−32.11%

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

12.3 days to cover short interest

Above its 50-day average, below its 200-day

32% of the way up its 52-week range

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

12.3 days to cover short interest

Above its 50-day average, below its 200-day

32% of the way up its 52-week range